Candida Enteritis Diagnoses in the United States: Prevalence and Clinical Insights from a Large Commercial Insurance Database.

Kaitlin Benedict, Jeremy A W Gold, Mark Pimentel

Abstract read

In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kaitlin BenedictMycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-9, Atlanta, GA, USA. jsy8@cdc.gov.ORCID http://orcid.org/0000-0003-0458-2493

Jeremy A W GoldMycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-9, Atlanta, GA, USA.

Mark PimentelMedically Associated Science and Technology Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCandida overgrowth in the small intestine can cause non-specific gastrointestinal symptoms mimicking those of other conditions, making diagnosis challenging.

aimsTo describe the characteristics of patients with Candida-related intestinal illness in a large US commercial health insurance claims dataset.

methodsWe used the Merative™ MarketScan® Commercial/Medicare Database to identify patients who received Candida enteritis diagnosis codes.

resultsWe identified 3,710 patients. Rates were higher among women (20.3/100,000), patients ages 35-44 (19.3/100,000) and in the West (28.1/100,000). Fatigue (44%) and abdominal pain (26%) were common symptoms. Few patients (6%) received an esophagogastroduodenoscopy, the preferred diagnostic method, and 38% received systemic antifungal therapy.

conclusionsIncreased healthcare provider awareness about proper diagnosis and treatment of intestinal Candida overgrowth could be beneficial.

Indexed as

CandidiasisEnteritisAdolescentAdultAgedAged, 80 and overAntifungal AgentsCandidaChild, PreschoolDatabases, FactualFemaleHumansMaleMiddle AgedPrevalenceUnited StatesAntifungal AgentsCandidaEnteritisFungiHealthInsuranceIntestine, smallYeasts

Identifiers

PMID41991776

DOI10.1007/s10620-026-09905-7

PMCPMC13522055

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.